H.C. Wainwright raised the firm’s price target on Palvella Therapeutics (PVLA) to $255 from $200 and keeps a Buy rating on the shares. Phase 3 SELVA data, with the mLM-IGA primary endpoint demonstrating a statistically significant 2.13-point mean change, is “a clear and decisive win,” says the analyst, who believes that the efficacy demonstrated in the SELVA trial will likely result in strong and continued uptake among patients if approved.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Reports Positive Phase 3 Data for QTORIN Gel
- Palvella Reports Positive Phase 3 Data for QTORIN
- Palvella Therapeutics’ qtorin meets primary endpoint in lymphatic malformations
- Palvella Therapeutics (PVLA): Mechanistic Validation, Unmet Need, and Pivotal Trial Catalysts Underpin Buy Rating
- Palvella Therapeutics management to meet virtually with Craig-Hallum